沙格列汀联合二甲双胍治疗2型糖尿病的疗效观察

摘要

OBJECTIVE: To probe into the efficacy of saxagliptin combined with metformin in treatment of type Ⅱ diabetes mellitus. METHODS: 200 patients with type Ⅱ diabetes mellitus admitted into Shunde Hospital of Guangzhou University of Chinese Medicine from Jun. 2017 to Jun. 2018 were selected and randomly divided into control group and observation group, with 100 cases in each. The control group was treated with metformin, while the observation group was given saxagliptin combined with metformin. The clinical efficacy, incidences of adverse drug reactions, blood glucose levels [fasting plasma glucose (FPG), 2 h postprandial blood glucose (2 hPG) and glycosylated hemoglobin (HbA1c) ] can body mass index (BMI) of two groups were observed. RESULTS: The total effective rate of observation group was 92.0％ (92/100), which was significantly higher than that of the control group (72.0％, 72/100), with statistically significant difference (P＜0.05); the incidence of adverse drug reactions of observation group was 4.0％ (4/100), which was significantly lower than that of the control group (12.0％, 12/100), with statistically significant difference (P＜0.05); after treatment, the FPG, 2 hPG, HbA1c and BMI levels of observation group were significantly better than that of the control group, with statistically significant differences (P＜0.05). CONCLUSIONS: The efficacy of saxagliptin combined with metformin in treatment of type Ⅱ diabetes mellitus is remarkable and more significant than that of metformin alone, which can control patients' blood glucose and BMI, with few adverse drug reactions and high safety.%目的:探讨沙格列汀联合二甲双胍治疗2型糖尿病的疗效.方法:选取2017年6月至2018年6月广州中医药大学顺德医院收治的2型糖尿病患者200例, 随机分为对照组和观察组, 每组100例.对照组患者给予二甲双胍治疗, 观察组患者给予沙格列汀联合二甲双胍治疗.观察两组患者的临床疗效、不良反应发生情况、血糖水平[空腹血糖 (FPG) 、餐后2 h血糖 (2 hPG) 及糖化血红蛋白 (HbA1c) ]及体质量指数 (BMI).结果:观察组患者的总有效率为92.0％ (92/100), 明显高于对照组的72.0％ (72/100), 差异有统计学意义 (P＜0.05);观察组患者的不良反应发生率为4.0％ (4/100), 明显低于对照组的12.0％ (12/100), 差异有统计学意义 (P＜0.05);治疗后, 观察组患者FPG、2 hPG、HbA1c及BMI水平明显优于对照组, 差异均有统计学意义 (P＜0.05).结论:沙格列汀联合二甲双胍治疗2型糖尿病的疗效显著, 较单用二甲双胍更具优势, 可控制患者血糖及体质量, 且不良反应少, 安全性较高.